Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.

Aged Antibodies, Neutralizing / blood Autoantibodies / blood COVID-19 / immunology Female Humans Intensive Care Units Interferon Type I / immunology Male Middle Aged Retrospective Studies SARS-CoV-2
COVID-19 SARS-CoV-2 acute kidney injury auto-antibodies type I interferons

Journal

Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137

Informations de publication

Date de publication:
11 2021
Historique:
received: 13 07 2021
accepted: 08 09 2021
pubmed: 28 9 2021
medline: 1 12 2021
entrez: 27 9 2021
Statut: ppublish

Résumé

It is important to predict which patients infected by SARS-CoV-2 are at higher risk of life-threatening COVID-19. Several studies suggest that neutralizing auto-antibodies (auto-Abs) against type I interferons (IFNs) are predictive of critical COVID-19 pneumonia. We aimed to test for auto-Abs to type I IFN and describe the main characteristics of COVID-19 patients admitted to intensive care depending on whether or not these auto-Abs are present. Retrospective analysis of all COVID-19 patients admitted to an intensive care unit (ICU) in whom samples were available, from March 2020 to March 2021, in Barcelona, Spain. A total of 275 (70.5%) out of 390 patients admitted to ICU were tested for type I IFNs auto-antibodies (α2 and/or ω) by ELISA, being positive in 49 (17.8%) of them. Blocking activity of plasma diluted 1/10 for high concentrations (10 ng/mL) of IFNs was proven in 26 (9.5%) patients. Almost all the patients with neutralizing auto-Abs were men (92.3%). ICU patients with positive results for neutralizing IFNs auto-Abs did not show relevant differences in demographic, comorbidities, clinical features, and mortality, when compared with those with negative results. Nevertheless, some laboratory tests (leukocytosis, neutrophilia, thrombocytosis) related with COVID-19 severity, as well as acute kidney injury (17 [65.4%] vs. 100 [40.2%]; p = 0.013) were significantly higher in patients with auto-Abs. Auto-Abs neutralizing high concentrations of type I IFNs were found in 9.5% of patients admitted to the ICU for COVID-19 pneumonia in a hospital in Barcelona. These auto-Abs should be tested early upon diagnosis of SARS-CoV-2 infection, as they account for a significant proportion of life-threatening cases.

Sections du résumé

BACKGROUND
It is important to predict which patients infected by SARS-CoV-2 are at higher risk of life-threatening COVID-19. Several studies suggest that neutralizing auto-antibodies (auto-Abs) against type I interferons (IFNs) are predictive of critical COVID-19 pneumonia.
OBJECTIVES
We aimed to test for auto-Abs to type I IFN and describe the main characteristics of COVID-19 patients admitted to intensive care depending on whether or not these auto-Abs are present.
METHODS
Retrospective analysis of all COVID-19 patients admitted to an intensive care unit (ICU) in whom samples were available, from March 2020 to March 2021, in Barcelona, Spain.
RESULTS
A total of 275 (70.5%) out of 390 patients admitted to ICU were tested for type I IFNs auto-antibodies (α2 and/or ω) by ELISA, being positive in 49 (17.8%) of them. Blocking activity of plasma diluted 1/10 for high concentrations (10 ng/mL) of IFNs was proven in 26 (9.5%) patients. Almost all the patients with neutralizing auto-Abs were men (92.3%). ICU patients with positive results for neutralizing IFNs auto-Abs did not show relevant differences in demographic, comorbidities, clinical features, and mortality, when compared with those with negative results. Nevertheless, some laboratory tests (leukocytosis, neutrophilia, thrombocytosis) related with COVID-19 severity, as well as acute kidney injury (17 [65.4%] vs. 100 [40.2%]; p = 0.013) were significantly higher in patients with auto-Abs.
CONCLUSION
Auto-Abs neutralizing high concentrations of type I IFNs were found in 9.5% of patients admitted to the ICU for COVID-19 pneumonia in a hospital in Barcelona. These auto-Abs should be tested early upon diagnosis of SARS-CoV-2 infection, as they account for a significant proportion of life-threatening cases.

Identifiants

DOI: 10.1007/s10875-021-01136-x PMID: 34570326 PMC: PMC8475877
pubmed: 34570326
doi: 10.1007/s10875-021-01136-x
pii: 10.1007/s10875-021-01136-x
pmc: PMC8475877
doi:

Substances chimiques

Antibodies, Neutralizing 0
Autoantibodies 0
Interferon Type I 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1733-1744

Subventions

Organisme : NIH HHS
ID : R01AI088364
Pays : United States
Organisme : NHGRI NIH HHS
ID : UM1HG006504
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : fisher center for alzheimer's research foundation
ID : ANR-10-IAHU-01
Organisme : NIH HHS
ID : UL1 TR001866
Pays : United States
Organisme : fundació la marató de tv3
ID : 202115-30-31
Organisme : NIAID NIH HHS
ID : R01 AI088364
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI163029
Pays : United States
Organisme : NHGRI NIH HHS
ID : U24 HG008956
Pays : United States
Organisme : NHGRI NIH HHS
ID : U24HG008956
Pays : United States
Organisme : horizon 2020
ID : 824110
Organisme : NCATS NIH HHS
ID : UL1 TR001866
Pays : United States

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;17: 105924. https://doi.org/10.1016/j.ijantimicag.2020.105924 .
doi: 10.1016/j.ijantimicag.2020.105924
Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;19: 105948. https://doi.org/10.1016/j.ijantimicag.2020.105948 .
doi: 10.1016/j.ijantimicag.2020.105948
WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020.  https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 . Accessed 14 Jun 2021.
Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol. 2020;35(12):1123–38. https://doi.org/10.1007/s10654-020-00698-1 .
doi: 10.1007/s10654-020-00698-1 pubmed: 33289900 pmcid: 7721859
Zhang Q, Bastard P, Bolze A, Jouanguy E, Zhang SY, Cobat A, et al. Life-threatening COVID-19: defective interferons unleash excessive inflammation. Med (N Y). 2020;1(1):14–20. https://doi.org/10.1016/j.medj.2020.12.001 .
doi: 10.1016/j.medj.2020.12.001
Rubio-Rivas M, Ronda M, Padulles A, Mitjavila F, Riera-Mestre A, García-Forero C, et al. Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness. Int J Infect Dis. 2020;101:290–7. https://doi.org/10.1016/j.ijid.2020.09.1486 .
doi: 10.1016/j.ijid.2020.09.1486 pubmed: 33035673 pmcid: 7537652
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 .
doi: 10.1016/S0140-6736(20)30183-5 pubmed: 31986264 pmcid: 31986264
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43. https://doi.org/10.1001/jamainternmed.2020.0994 .
doi: 10.1001/jamainternmed.2020.0994 pubmed: 32167524
Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of COVID-19: current state of the science. Immunity. 2020;52(6):910–41. https://doi.org/10.1016/j.immuni.2020.05.002 .
doi: 10.1016/j.immuni.2020.05.002 pubmed: 32505227 pmcid: 7200337
Anastassopoulou C, Gkizarioti Z, Patrinos GP, Tsakris A. Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. Hum Genomics. 2020;14(1):40. https://doi.org/10.1186/s40246-020-00290-4 .
doi: 10.1186/s40246-020-00290-4 pubmed: 33092637 pmcid: 7578581
Novelli G, Biancolella M, Mehrian-Shai R, Colona VL, Brito AF, Grubaugh ND, et al. COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy. Hum Genomics. 2021;15(1):27. https://doi.org/10.1186/s40246-021-00326-3 .
doi: 10.1186/s40246-021-00326-3 pubmed: 33966626 pmcid: 8107019
Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570. https://doi.org/10.1126/science.abd4570 .
doi: 10.1126/science.abd4570 pubmed: 32972995 pmcid: 7857407
Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with lifethreatening COVID-19. Science. 2020;370(6515):eabd4585. https://doi.org/10.1126/science.abd4585 .
doi: 10.1126/science.abd4585 pubmed: 32972996 pmcid: 7857397
Koning R, Bastard P, Casanova JL, Brouwer MC, van de Beek D, et al. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 2021;9:1–3. https://doi.org/10.1007/s00134-021-06392-4 .
doi: 10.1007/s00134-021-06392-4
van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, et al. Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19. bioRxiv [Preprint]. 2021 Mar 10:2021.03.09.434529. https://doi.org/10.1101/2021.03.09.434529 .
Troya J, Bastard P, Planas-Serra L, Ryan P, Ruiz M, de Carranza M, et al. Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. J Clin Immunol. 2021;13:1–9. https://doi.org/10.1007/s10875-021-01036-0 .
doi: 10.1007/s10875-021-01036-0
Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283–8. https://doi.org/10.1038/s41586-021-03631-y .
doi: 10.1038/s41586-021-03631-y pubmed: 34010947
Bastard P, Lévy R, Henriquez S, Bodemer C, Szwebel TA, Casanova JL. Interferon-β therapy in a patient with incontinentia pigmenti and autoantibodies against type I IFNs infected with SARS-CoV-2. J Clin Immunol. 2021;25:1–3. https://doi.org/10.1007/s10875-021-01023-5 .
doi: 10.1007/s10875-021-01023-5
de Prost N, Bastard P, Arrestier R, Fourati S, Mahévas M, Burrel S, et al. Plasma exchange to rescue patients with autoantibodies against type I interferons and life-threatening COVID-19 pneumonia. J Clin Immunol. 2021;41(3):536–44. https://doi.org/10.1007/s10875-021-00994-9 .
doi: 10.1007/s10875-021-00994-9 pubmed: 33616813
Vinh DC, Abel L, Bastard P, Cheng MP, Condino-Neto A, Gregersen PK, et al. Harnessing type I IFN immunity against SARS-CoV-2 with early administration of IFN-β. J Clin Immunol. 2021;8:1–18. https://doi.org/10.1007/s10875-021-01068-6 .
doi: 10.1007/s10875-021-01068-6
Schulman S, Kearon C; Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4. https://doi.org/10.1111/j.1538-7836.2005.01204.x .
Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204. https://doi.org/10.1186/cc11454 .
doi: 10.1186/cc11454 pubmed: 23394211 pmcid: 4057151
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10. https://doi.org/10.1001/jama.2016.0287 .
doi: 10.1001/jama.2016.0287 pubmed: 26903338 pmcid: 4968574
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707–10. https://doi.org/10.1007/BF01709751 .
Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718–24. https://doi.org/10.1126/science.abc6027 .
doi: 10.1126/science.abc6027 pubmed: 32661059 pmcid: 32661059
Bastard P, Zhang Q, Cobat A, Jouanguy E, Zhang SY, Abel L, et al. Insufficient type I IFN immunity underlies life-threatening COVID-19 pneumonia. C R Biol. 2021;344(1):19–25. https://doi.org/10.5802/crbiol.36 .
doi: 10.5802/crbiol.36 pubmed: 34213846
Kellum JA, van Till JWO, Mulligan G. Targeting acute kidney injury in COVID-19. Nephrol Dial Transplant. 2020;35(10):1652–62. https://doi.org/10.1093/ndt/gfaa231 .
doi: 10.1093/ndt/gfaa231 pubmed: 33022712
Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2021;12(1):2506. https://doi.org/10.1038/s41467-021-22781-1 .
doi: 10.1038/s41467-021-22781-1 pubmed: 33947851 pmcid: 8096808

Auteurs

Xavier Solanich (X)

Department of Internal Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. xsolanich@bellvitgehospital.cat.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. xsolanich@bellvitgehospital.cat.
ORCID: 0000-0002-2572-2187

Raúl Rigo-Bonnin (R)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Clinical Laboratory, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Victor-David Gumucio (VD)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Intensive Care, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Paul Bastard (P)

Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, EU, France.
Imagine Institute, University of Paris, Paris, EU, France.
St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.

Jérémie Rosain (J)

Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, EU, France.
Imagine Institute, University of Paris, Paris, EU, France.

Quentin Philippot (Q)

Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, EU, France.
Imagine Institute, University of Paris, Paris, EU, France.

Xosé-Luis Perez-Fernandez (XL)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Intensive Care, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Maria-Paz Fuset-Cabanes (MP)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Intensive Care, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Miguel-Ángel Gordillo-Benitez (MÁ)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Intensive Care, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Guillermo Suarez-Cuartin (G)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Respiratory Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Enric Boza-Hernandez (E)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Anesthesiology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Antoni Riera-Mestre (A)

Department of Internal Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.

Alba Parra-Martínez (A)

Infection in Immunocompromised Pediatric Patients Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Roger Colobran (R)

Immunology Division, Genetics Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Diagnostic Immunology Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d' Hebron Barcelona Hospital Campus, Barcelona, Spain.
Immunology Unit. Department of Cellular Biology, Physiology and Immunology, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

Arnau Antolí (A)

Department of Internal Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Sergio Navarro (S)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Immunology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Gemma Rocamora-Blanch (G)

Department of Internal Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Mario Framil (M)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Immunology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Laura Calatayud (L)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Microbiology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Xavier Corbella (X)

Department of Internal Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain.

Jean-Laurent Casanova (JL)

Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, EU, France.
Imagine Institute, University of Paris, Paris, EU, France.
St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
Howard Hughes Medical Institute, New York, NY, USA.

Francisco Morandeira (F)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Immunology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Joan Sabater-Riera (J)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Intensive Care, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Pre-existing Autoantibodies Neutralizing High...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Pre-existing Autoantibodies Neutralizing High...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Autoanticorps › Pre-existing Autoantibodies Neutralizing High...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Pre-existing Autoantibodies Neutralizing High...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Pre-existing Autoantibodies Neutralizing High...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Établissements de santé › Unités hospitalières › Unités de soins intensifs › Pre-existing Autoantibodies Neutralizing High...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Interféron de type I › Pre-existing Autoantibodies Neutralizing High...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Pre-existing Autoantibodies Neutralizing High...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Pre-existing Autoantibodies Neutralizing High...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Pre-existing Autoantibodies Neutralizing High...